Why Sun Pharma’s hefty bid for Organon has divided investors
The potential $10-billion deal has split the market, pitting those who trust chairman Dilip Shanghvi’s track record of value creation against skeptics wary of Organon’s $8.9 billion debt pile and recent governance issues.
The potential $10-billion deal has split the market, pitting those who trust chairman Dilip Shanghvi’s track record of value creation against skeptics wary of Organon’s $8.9 billion debt pile and recent governance issues.
What's Your Reaction?
Economist Admin
Admin managing news updates, RSS feed curation, and PR content publishing. Focused on timely, accurate, and impactful information delivery.
